Welcome to our dedicated page for Bionano Genomics news (Ticker: BNGO), a resource for investors and traders seeking the latest updates and insights on Bionano Genomics stock.
Bionano Genomics, Inc. reports developments in genome analysis solutions built around optical genome mapping (OGM), diagnostic services, software and nucleic acid extraction technologies. Company updates commonly address OGM applications in cytogenetics, rare disease research, hematologic malignancies, reproductive disorders and other genomic-analysis workflows, including published studies comparing OGM with karyotyping, FISH, chromosomal microarrays, next-generation sequencing and long-read sequencing.
Recurring news also covers financial results, revenue outlooks, scientific-meeting presentations, Bionano Symposium activity, use of VIA™ software, the Ionic® system and Bionano Laboratories diagnostic testing services. Governance updates include board and executive leadership changes at the Nasdaq-listed life sciences instrumentation company.
Bionano Genomics (BNGO) reports results from a University Hospitals Leuven study demonstrating the effectiveness of their Saphyr system in analyzing acute lymphoblastic leukemia (ALL). The optical genome mapping (OGM) technique showed a 100% concordance with traditional methods and reduced turnaround time from 4 weeks to 1 week. Key findings include a 50% reduction in cost per sample, a higher assay success rate, and additional pathogenic findings in 5% more cases. The study supports future OGM-based assays for leukemia and other conditions.
Bionano Genomics (Nasdaq: BNGO) presented data at the 2021 European Cytogenomics Conference, showcasing the advantages of optical genome mapping (OGM) over traditional cytogenetics in leukemia research. Key studies revealed 100% concordance in pediatric leukemia diagnoses, uncovering new clinically relevant information in 60% of cases. OGM also demonstrated improved prognostic capabilities in chronic lymphocytic leukemia, with 45% of cases benefiting from additional insights. Overall, the findings underscore OGM's potential to enhance diagnostic accuracy and treatment strategies in hematological malignancies.
Bionano Genomics (BNGO) showcased its optical genome mapping (OGM) technology at the 2021 European Cytogenomics Conference (ECA), indicating its increasing adoption for genomic analysis in leukemia and genetic diseases. The event featured nine presentations highlighting OGM's advantages, such as 100% concordance with traditional techniques and significant cost and time reductions. Key findings included enhanced prognostic accuracy and identification of clinically relevant variants. CEO Erik Holmlin emphasized the potential for OGM's continued expansion in clinical research applications.
Bionano Genomics (Nasdaq: BNGO) announced two significant peer-reviewed studies published in the American Journal of Human Genetics. Conducted by leading European institutions, these studies validate the effectiveness of optical genome mapping (OGM) as a superior method for analyzing structural variants (SVs) in genetic diseases and hematological malignancies. OGM demonstrated 100% concordance with traditional methods like FISH and karyotyping, offering enhanced resolution for detecting variants. The research emphasizes OGM's potential to revolutionize cytogenetic analysis and its ready application in clinical settings.
Bionano Genomics (BNGO) has made strides in the Chinese market with the adoption of its Saphyr® System for optical genome mapping (OGM) by WeHealth Shanghai. Announced at the Structural Variation Symposium, WeHealth highlighted the launch of a comprehensive genome-analysis offering. Key presentations included successful applications of OGM for prenatal testing in muscular dystrophy and improved diagnostic workflows for hemophilia A.
CEO Erik Holmlin emphasized the company’s ongoing investment in commercial operations in China, aiming for expanded adoption of Saphyr in the reproductive health sector.
Bionano Genomics (Nasdaq: BNGO) announced participation in the 6th Annual International Conference of the Board of Genetic Counseling India from July 2-4, 2021. Chief Medical Officer Dr. Alka Chaubey will discuss optical genome mapping (OGM) in genetic counseling on July 3 at 9:25 am IST. Dr. Yassmine Akkari will present on OGM's role in Acute Myelogenous Leukemia at 4:10 pm IST the same day. The conference promotes genetic education and has over 2,000 global delegates. Bionano is a Diamond Sponsor of the event.
Bionano Genomics, Inc. (Nasdaq: BNGO) announced that its CEO, Erik Holmlin, will present at the 2021 Ladenburg Thalmann Healthcare Conference on July 13 at 4:30 PM EDT. The presentation will provide an overview of the company and will be accessible on Bionano's Investors section of their website. A recorded version will be available for 30 days post-event. Bionano specializes in genome analysis with its Saphyr system, supporting genetic research and diagnostic testing for neurodevelopmental disorders.
Bionano Genomics, Inc. (Nasdaq: BNGO) has been added to the US small-cap Russell 2000® Index, effective June 28, 2021, as part of the Russell indexes reconstitution. This membership enhances Bionano's visibility to institutional investors and reflects the growing awareness of optical genome mapping (OGM) in genome analysis. Russell indexes are widely utilized by investment managers, with approximately $10.6 trillion in assets benchmarked against them. The inclusion is expected to boost Bionano's profile as it develops its Saphyr system for genomic research and diagnostics.
Bionano Genomics (Nasdaq: BNGO) announced the appointment of Richard Shippy as Chief Business Officer. With over 20 years in life sciences, Shippy has a proven track record at Affymetrix, where he developed the CytoScan HD Array, and at Illumina. He will lead product strategy and market expansion for Bionano's optical genome mapping (OGM) technology, aiming to enhance the detection of structural variations (SVs). CEO Erik Holmlin expressed confidence in Shippy's ability to drive the company's growth and impact in cytogenetics.
Bionano Genomics (BNGO) has appointed Jason Priar as Chief Commercial Officer. Priar is a seasoned leader known for scaling businesses in genetic diseases and cancer testing, previously leading GeneDx to significant revenue growth. His role will focus on enhancing sales and market access for the company's Saphyr® system and Lineagen’s diagnostic services. CEO Erik Holmlin expressed confidence in Priar's ability to drive global adoption of Bionano's optical genome mapping technology, emphasizing his industry expertise and established relationships with payers.